drugset / Trial / NCT00956202

A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years

NCT00956202

Phase 2 Completed 303 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to generate data on immunogenicity and safety of the monovalent H1N1 vaccine in support of the development and registration. Primary objectives: * To describe the immune response to vaccines 21 days after each vaccination in all participants. * To describe the antibody persistence eight months after the first vaccine administration using HAI method, in a subset of participants who received two injections. * To describe the immune response against the A/H1N1 strain using HAI method 21 days after a vaccination with the 2010-2011 NH seasonal TIV administered approximately 13 months after the first vaccination in the subset of participants who received two injections. * To describe the safety profile of each vaccine in all participants.

Timeline

Start
2009-08
Primary completion
2010-09
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Influenza Virus Vaccine Vaccine 0.5 ml
Subject Swine A/H1N1 influenza vaccine Vaccine 0.5 ml Intramuscular
Subject Swine A/H1N1 influenza vaccine Vaccine 0.5 ml Intramuscular

Indications